Mateon Therapeutics, Inc.
MATN
MATN was delisted on the 7th of December, 2016.
21 hedge funds and large institutions have $1.42M invested in Mateon Therapeutics, Inc. in 2016 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 3 closing their positions.
133% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 3
9% less capital invested
Capital invested by funds: $1.57M → $1.42M (-$147K)
13% less funds holding
Funds holding: 24 → 21 (-3)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $13K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$33.3K |
| 2 |
SKK
Shepherd Kaplan Krochuk
Boston,
Massachusetts
|
+$23.7K |
| 3 |
Goldman Sachs
New York
|
+$9.62K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$3.33K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$1.34K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$14K |
| 2 |
GC
Guggenheim Capital
Chicago,
Illinois
|
-$10K |
| 3 |
ARTA
A.R.T. Advisors
New York
|
-$7K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$5.39K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
-$2.42K |
MATN Hedge Fund Activity: Q3 2016 in Review
21 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Mateon Therapeutics, Inc. (MATN) for Q3 2016, worth a combined $1.42M — down 9.4% from $1.57M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of MATN and 0 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 7 added.
The largest buyer was Renaissance Technologies, adding an estimated $33.3K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $14K sold.
- 21 institutional investors held Mateon Therapeutics, Inc. (MATN) as of Q3 2016, down from 24 in Q2 2016.
- Funds reported $1.42M of Mateon Therapeutics, Inc. stock for Q3 2016, down 9.4% quarter-over-quarter.
- 0 funds opened new Mateon Therapeutics, Inc. positions in Q3 2016 and 3 closed out, a net change of -3 holders.
- The largest Mateon Therapeutics, Inc. buyer in Q3 2016 was Renaissance Technologies, an estimated $33.3K added.
- The largest Mateon Therapeutics, Inc. seller in Q3 2016 was Susquehanna International Group, an estimated $14K sold.
Based on aggregated 13F filings for Q3 2016.